Analysis – Page 2 – Goldea Capital

Bond Provides Business Update and Reports 2026 First Quarter Financial Results

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Strategic First Quarter Investments Lay Foundation for Long-Term Growth NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today provided a business update and reported financial results for the first quarter of 2026 ended March 31, 2026. Business HighlightsStrong Enterprise Demand: Continued strong demand from enterprise customers, with deployments expanding across retail, telecommunications, financial services, pharmaceuticals and multinational organizations. Global Expansion: Expanded global footprint, with operations now spanning multiple regions, countries and languages. Multi-Channel Growth Strategy: Continued execution of Bond’s multi-channel go-to-market strategy...

Lifeward Reports First Quarter 2026 Financial Results

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 15, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation...

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026. “We continue to make meaningful progress advancing the belapectin program and further analyzing the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. The additional analyses, including biomarker data, continue to support the potential of belapectin to impact disease progression in this high-risk population. We are looking forward to our upcoming data presentations at EASL later this month and our in-person Type-C meeting with FDA this quarter. Additionally, we remain focused on engaging with potential partners and leading experts to help determine...

CAPREIT Announces May 2026 Distribution

Written by Customer Service on May 15, 2026. Posted in Dividend Reports And Estimates.

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, May 15, 2026 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today its May 2026 monthly distribution in the amount of $0.12916 per Unit (or $1.55 on an annualized basis). The May 2026 distribution will be payable on June 15, 2026 to Unitholders of record at the close of business on May 29, 2026. About CAPREIT CAPREIT is Canada’s largest publicly traded provider of quality rental housing. As at March 31, 2026, CAPREIT owns approximately 45,400 residential apartment suites and townhomes (excluding approximately 200 suites classified as assets held for sale), that are well-located across Canada and, to a lesser extent, the Netherlands, with a total fair value of...

Bayport Management Ltd Q1 2026 Financial Statements

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Bayport Management Ltd Q1 2026 Financial StatementsAttachmentsGroup Quarterly report_March 2026Group Quarterly report_March 2026

Bayport Intermediate Holdco PLC Q1 2026 Financial Statements

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Bayport Intermediate Holdco PLC Q1 2026 Financial StatementsAttachmentQuarterly report IH PLC_March 2026

Safe Pro Reports Record 560% Revenue Growth in First Quarter as Artificial Intelligence Sales Surge 2,400%, Delivering AI Gross Margins Over 72%

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

Increased Government Sales Pipeline Driving Momentum Following Successful U.S. Army Exercises and Demonstrations in Q1 AVENTURA, Fla., May 15, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (Safe Pro or the Company), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced financial results for the quarter ended March 31, 2026 reflecting the significant impact of a recently commercialized AI-powered Edge compute solution subcontract. First Quarter 2026 Financial and Recent Operational Highlights Include:Record Revenue Growth and High Margins Driven by AI Product SalesRecord quarterly revenue of $1,220,129 represents a 560% increase over $184,802 reported in the first quarter of 2025. Safe Pro AI quarterly revenue surged over 2,400%, driven by new...

FRO – Invitation to Q1 2026 Results Conference Call and Webcast

Written by Customer Service on May 15, 2026. Posted in Public Companies.

Frontline plc.’s preliminary first quarter 2026 results will be released on Friday May 22, 2026, and a webcast and conference call will be held at 3:00 p.m. CEST (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q1 2026 Webcast b. Conference CallParticipants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered. Frontline plc Q1 2026 Conference Call A Q&A session will be held after the teleconference/webcast....

Abaxx Provides Corporate Milestone Update

Written by Customer Service on May 15, 2026. Posted in Public Companies.

TORONTO, May 15, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, provides an update on operational milestones and execution of the Company’s business strategy for the six-month period following its previous corporate update. As previously announced, the Company is hosting its Q1 2026 Earnings and Business Update Call on Tuesday, May 19th. For more information, see “Q1 2026 Earnings Call” below. Abaxx Corporate Milestone Highlights Commercial DevelopmentTotal Abaxx Exchange volume increased...

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Written by Customer Service on May 15, 2026. Posted in Earnings Releases And Operating Results.

– New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting – – Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 – – 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden – – Ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals